The development of new therapies for cancer and other diseases is a daunting task requiring many years of effort and a substantial budget. The risks of failure are high.
The Schein Group has several decades of experience and a track record of success in assisting large international corporations and small startup companies in addressing a wide range of challenges including:
•FDA and EMEA Regulatory Strategies
Philip Schein, MD, DSc (Hon), FRCP
President, The Schein Group, Inc